PT  - JOURNAL ARTICLE
AU  - Ilke Sipahi
AU  - Stephen J. Nicholls
AU  - E. Murat Tuzcu
AU  - Steven E. Nissen
TI  - Interpreting the ASTEROID Trial
DP  - 2006 Oct 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 937--944
VI  - 73
IP  - 10
4099  - http://www.ccjm.org/content/73/10/937.short
4100  - http://www.ccjm.org/content/73/10/937.full
SO  - Cleve Clin J Med2006 Oct 01; 73
AB  - The ASTEROID trial (JAMA 2006; 295:1556–1565) showed that very intensive statin therapy with rosuvastatin 40 mg once daily results in highly significant regression of coronary atherosclerosis as assessed by serial intravascular ultrasonography (IVUS). The mean low-density lipoprotein cholesterol (LDL-C) level achieved with this regimen was 61 mg/dL, and the mean high-density lipoprotein cholesterol (HDL-C) level increased by 15%. While the merits of concomitant LDL-C-lowering and HDL-C-raising therapies remain to be determined, the results of the ASTEROID and other recent trials suggest that the optimal strategy for lipid-lowering in patients with coronary artery disease is to try for the lowest LDL-C level that can be attained without adverse effects.